Benzodiazepines: Uses, Dangers, and Clinical Considerations
Open accessThe DOI matches its Crossref record; 78 of the 85 references it cites were found in a registry or an index; 35 of the 151 sources its claims cite were checked for support.
Abstract
Benzodiazepines (BZDs) are among one of the most widely prescribed drug classes in the United States. BZDs are a class of psychoactive drugs known for their depressant effect on the central nervous system (CNS). They quickly diffuse through the blood-brain barrier to affect the inhibitory neurotransmitter GABA and exert sedative effects. Related to their rapid onset and immediate symptom relief, BZDs are used for those struggling with sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, and epilepsy. One of the debilitating side effects of BZDs is their addictive potential. The dependence on BZDs generally leads to withdrawal symptoms, requiring careful tapering of the medication when prescribed. Regular use of BZDs has been shown to cause severe, harmful psychological and physical dependence, leading to withdrawal symptoms similar to that of alcohol withdrawal. Some of these withdrawal symptoms can be life threatening. The current treatment for withdrawal is through tapering with clonazepam. Many drugs have been tested as a treatment for withdrawal, with few proving efficacious in randomized control trials. Future research is warranted for further exploration into alternative methods of treating BZD withdrawal. This call to action proves especially relevant, as those seeking treatment for BZD dependence and withdrawal are on the rise in the United States.
Overview
CoChat Summary
TL;DR
This narrative review summarizes benzodiazepine indications, adverse effects, dependence, withdrawal, and clinical management, emphasizing that BZDs remain widely prescribed despite substantial risks. It concludes that gradual tapering with a long-acting BZD such as clonazepam is current withdrawal treatment, but evidence for many alternative therapies is mixed and further research is needed.
Key findings
- BZDs are used for sleep, anxiety, spasticity due to CNS pathology, muscle relaxation, epilepsy, catatonia, and alcohol/BZD withdrawal; chronic use is linked to tolerance, dependence, and potentially life-threatening withdrawal similar to alcohol withdrawal.
- One cited study found a withdrawal rate of approximately 40% in people using long-acting BZDs for six or more months with abrupt cessation; another reported that the hazard of death was doubled in patients prescribed BZDs compared with controls, with 4 excess deaths in the anxiolytic group over an average of 7.6 years.
- Among substance-using populations, 54% of oxycodone abusers were also dependent on a BZD, and 64% of heroin users were also abusing BZDs.
- Withdrawal treatment evidence is mixed: a 7-day IV flumazenil infusion led to abstinence in over half of subjects in one study, propranolol still left 27–45% of patients with withdrawal symptoms in one study and approximately 80% in another severely dependent group, and oxcarbazepine shortened withdrawal to 11–19 days in an uncontrolled case series.
Methods
- Design: narrative review of benzodiazepine pharmacology, clinical indications, dangers, misuse, withdrawal, and treatment.
- Data/sample: no primary sample; the paper synthesizes published literature, including clinical studies, cohort studies, case reports, and reviews.
- Main analysis: qualitative narrative synthesis of cited evidence, with no stated systematic search strategy, meta-analysis, or formal risk-of-bias assessment.
Limitations
- The paper states that many drugs tested for BZD withdrawal have shown mixed results, with few proving efficacious in randomized controlled trials, and that no set taper schedule has been validated in the current literature.
- The paper repeatedly notes limitations of cited studies, including small sample sizes, lack of double-blinding, uncontrolled designs, and potential underreporting of relapse.
- Evident from the text: as a narrative review, it does not describe a systematic search, inclusion criteria, or quantitative synthesis, so its conclusions depend on the selected cited studies rather than a formal meta-analytic estimate.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 11 Not valid · 111 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Interestingly, a lower prevalence of withdrawal symptoms was noted in the experimental group without any change in pharmacologic treatment from control group [73].”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 5. Clinical Studies > 5.3. Educational Approaches to Benzodiazepine Withdrawal
What the sources say
- Disputedcites [73] Dyer A.H. Murphy C. Lawlor B. Kennelly S.P. NILVAD Study Group Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living with Mild to Moderate Alzheimer’s Disease: Results From NILVAD J. Am. Med. Dir. Assoc. 2020 21 194 200 10.1016/j.jamda.2019.08.006 31604674 sourceExperimental — accuracy not yet measured
The Study Design section says the experimental group received nilvadipine 8 mg daily while the control group received placebo for 18 months, contrary to the claim that pharmacologic treatment did not differ. The paper’s analysis concerns ongoing benzodiazepine use and cognitive and adverse outcomes; the passages found do not report a lower prevalence of withdrawal symptoms. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study showed a potential for cognitive decline after BZD use in the elderly, but at the same time did not find a link between their use and the development of Alzheimer’s dementia [73].”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 5. Clinical Studies > 5.4. Long-Term Effects of Benzodiazepine Use
What the sources say
- Disputedcites [73] Dyer A.H. Murphy C. Lawlor B. Kennelly S.P. NILVAD Study Group Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living with Mild to Moderate Alzheimer’s Disease: Results From NILVAD J. Am. Med. Dir. Assoc. 2020 21 194 200 10.1016/j.jamda.2019.08.006 31604674 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports no association between ongoing benzodiazepine-related drug use and cognitive scores after 18 months in people who already had mild to moderate Alzheimer’s disease. It also says lifetime exposure may be a risk factor for developing Alzheimer’s disease—not that the study found no link with its development. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study showed a potential for cognitive decline after BZD use in the elderly, but at the same time did not find a link between their use and the development of Alzheimer’s dementia [73].”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 5. Clinical Studies > 5.4. Long-Term Effects of Benzodiazepine Use
What the sources say
- Disputedcites [73] Dyer A.H. Murphy C. Lawlor B. Kennelly S.P. NILVAD Study Group Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living with Mild to Moderate Alzheimer’s Disease: Results From NILVAD J. Am. Med. Dir. Assoc. 2020 21 194 200 10.1016/j.jamda.2019.08.006 31604674 sourceExperimental — accuracy not yet measured
The Discussion says the study examined cognitive outcomes in people already diagnosed with mild to moderate Alzheimer’s disease, not whether BDZR use was linked to developing it. It also states that significant evidence suggests lifetime BDZR exposure may be a risk factor for Alzheimer’s disease in later life—the opposite of the attributed claim. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Despite the increase in risk, less than 13% of the non-overdose deaths were trauma related.”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 3. Benzodiazepine Use Dangers
What the sources say
- Could not verifycites [49] Park T.W. Saitz R. Ganoczy D. Ilgen M.A. Bohnert A.S.B. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study BMJ 2015 350 h2698 10.1136/bmj.h2698 26063215 PMC4462713 sourceExperimental — accuracy not yet measured
The Methods section defines overdose deaths, and the Results report overdose death rates, but neither gives the causes of non-overdose deaths. Searches for trauma-related non-overdose deaths and the 13% figure found no passage addressing that proportion. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It was also reported that the risk of death in patients using less than 18 pills per year is increased by 3.6-fold [48].”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 3. Benzodiazepine Use Dangers
What the sources say
- Partly supportedcites [48] Abrahamsson T. Berge J. Öjehagen A. Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—A nation-wide register-based open cohort study Drug Alcohol Depend. 2017 174 58 64 10.1016/j.drugalcdep.2017.01.013 28315808 sourceExperimental — accuracy not yet measured
Section 3.3 (Main analyses; page unavailable) reports associations between some sedative prescriptions and increased all-cause mortality. It does not report a subgroup using fewer than 18 pills per year or a 3.6-fold increase in death risk; searches for those terms found no such result. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
102 more claims · 22 with their cited sources checked
Create a free account to see all 159 claims and to verify the 12 references still open.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 3
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most existing guidance recommend a flexible approach to tapering, reducing the dose at a rate dictated by each patient’s ability to tolerate withdrawal symptoms and allowing the process to take as long as patients need.2,59,69,79,80,100–102”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Factors including use of shorter acting BZD, higher dose, and longer duration of treatment contribute to a higher likelihood of physical dependence and risk of severe withdrawal.59”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“The presence of certain psychiatric symptoms has been associated with an increased likelihood of experiencing more severe withdrawal symptoms, which can present challenges to successful completion of BZD tapering.59,84”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 1. Introduction > 1.2. Duration of Treatment
“Long-term use is defined as two or more months at a therapeutic dose”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 4. Withdrawal > 4.4. Special Populations and Withdrawal
“Cessation after long-term usage (greater than two weeks) has even shown in some individual’s the inability to return to cognitive baseline.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 3. Benzodiazepine Use Dangers
“This is more significant than the study by Weich et al. [47] which found a 2-fold increased hazard of death in 7 years.”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > References
“47. Kripke D.F. Langer R.D. Kline L.E. Hypnotics’ association with mortality or cancer: A matched cohort study BMJ Open 2012 2 10.1136/bmjopen-2012-000850 PMC3293137 22371848”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 2. Benzodiazepine Overuse Pathology, Misuses, and Complications > 2.5. Issues with Clinical Use of Benzodiazepine
“BZDs lead to long-lasting impairment of episodic implicit memory while it only impairs implicit memory transiently [1].”
§ Benzodiazepines: Uses, Dangers, and Clinical Considerations > 2. Benzodiazepine Overuse Pathology, Misuses, and Complications > 2.5. Issues with Clinical Use of Benzodiazepine
“while it only impairs implicit memory transiently [1].”
Citations
Cites
McLean, C. P., Asnaani, A., Litz, B. T., & Hofmann, S. G. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.03.006 · Cited by 2,519 · cited 1×
“Mclean et al. 2011 reported that the diagnosis of anxiety and stress disorders has a higher prevalence in women, which can explain the discrepancies in the prescription for men vs. women [30].”
BackgroundIt’s time to revise the definition of status epilepticus
Lowenstein, D. H., Bleck, T., & Macdonald, R. L. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02000.x · Cited by 805 · cited 1×
“Neuronal damage may begin as soon as five min of seizure activity, so abortion with BZDs or other CNS sedatives is imperative [14].”
BackgroundBenzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Benzodiazepine pharmacology and central nervous system-mediated effects.
(2013) · Europe PMC (PubMed Central) · Cited by 650
Self-citationGuidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579 · cited 1×
“They showed that benzodiazepine increased the incidence of non-overdose death in these patients which may be attributed to its impairment of cognition, sensory, and motor skills and increased risk of fall leading to injuries [49].”
BackgroundBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573 · cited 1×
“Some additional side effects of concern include aggressive behavior and expressing anger towards others in between 1% and 20% of users [17].”
BackgroundBenzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558 · cited 1×
“It has been associated with increased risk for dementia [57,58].”
BackgroundBenzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 534
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479 · cited 1×
“It has been shown that patients diagnosed with substance use disorder have increased tendencies to misuse BZD compared to the general population [31].”
Background
Cited by
Hirjak, D., Rogers, J. P., Wolf, R. C., Kubera, K. M., Fritze, S., Wilson, J. E., Sambataro, F., Fricchione, G. L., Meyer‐Lindenberg, A., Ungvari, G. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00534-w · Cited by 106
“Therapy with benzodiazepines must always be monitored clinically because long-term usage, which may be necessary in particular patients, can result in the development of tolerance, dependency and the occurrence of withdrawal symptoms upon cessation, making prescribing difficult 217 .”
Ngcobo, N. N. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01466-0 · Cited by 199
“This increased susceptibility to sedation and psychomotor impairment in the elderly may be due to reduced drug clearance and higher plasma concentrations, as benzodiazepines are lipid-soluble [6, 86, 90].”
Rupprecht, R., Wetzel, C. H., Dorostkar, M. M., Herms, J. W., Albert, N. L., Schwarzbach, J. V., Schumacher, M., & Neumann, I. D. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01561-3 · Cited by 73
“However, their long-term use is hampered by side effects, such as tolerance development and abuse liability [2, 3].”
BackgroundNovel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
Edinoff, A. N., Nix, C. A., Odisho, A. S., Babin, C. P., Derouen, A. G., Lutfallah, S. C., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14030053 · Cited by 74
“As tranquilizers, benzodiazepines have a wide range of clinical use, most commonly for treating insomnia (temazepam) [15,20,21] and panic disorder (alprazolam, lorazepam, or clonazepam) [15,20,22–25].”
BackgroundSelf-citationBenzodiazepines in Alzheimer’s disease: beneficial or detrimental effects
Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01099-4 · Cited by 58
“Long-term effects of BDZs may induce dementia-like syndrome with augmentation of anxiety disorders and cognitive decline (Edinoff et al. 2021).”
Background
Metadata
- Authors
- Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D.
- Affiliations
- Louisiana State University (US)
- University of the Pacific (US)
- Corresponding author
- Edinoff, Amber N.
- Venue
- Neurology International
- Publisher
- MDPI AG
- Published
- 2021-11-10
- Volume
- 13
- Issue
- 4
- Pages
- 594-607
- ISSN
- 2035-8377 (ISSN-L)
- PMC
- PMC8629021
- OpenAlex
- W3212918570
- Cited by
- 340
- References
- 85
- Citations by year
- 2026: 96 · 2025: 102 · 2024: 91 · 2023: 43 · 2022: 8
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neurology International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Scholarly Commons (University of the Pacific) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- benzodiazepines, benzodiazepine dependence, benzodiazepine withdrawal, withdrawal symptoms, clonazepam, tapering, GABA, central nervous system depression, sleep disorders, anxiety, spasticity, epilepsy, drug addiction, alcohol withdrawal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines: Uses, Dangers, and Clinical Considerations. https://app.cochat.ai/papers/10.3390/neurolint13040059
- The paper
- Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology International. https://doi.org/10.3390/neurolint13040059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.